AVANIR Invites Investors to Webcast of Pacific Growth Equities Life Sciences Growth Conference Presentation
June 03 2005 - 2:31PM
Business Wire
AVANIR Pharmaceuticals, (AMEX:AVN) today announced that its
presentation at the Pacific Growth Equities Life Sciences Growth
Conference will be webcast live through the Company's web site at
http://www.avanir.com. Vice President and Chief Financial Officer
Gregory P. Hanson will be presenting at 9:30 am Pacific time on
June 8th from the conference in San Francisco. The live webcast
will be accessible through AVANIR's corporate website via a link on
the lower left side of the homepage. To access the webcast, please
log on to AVANIR's site approximately fifteen minutes prior to the
presentation to register and download any necessary audio software.
An archived version of the presentation will be available for 90
days following the conference. AVANIR Pharmaceuticals is a
pharmaceutical company focused on developing and commercializing
novel therapeutic products for the treatment of chronic diseases.
AVANIR's product candidates address therapeutic markets that
include central nervous system and cardiovascular disorders,
inflammation, and infectious disease. AVANIR expects to submit the
final module of its rolling new drug application to the U.S. Food
and Drug Administration for its lead product candidate,
Neurodex(TM), in mid-2005. Recently, AVANIR partnered its
preclinical research and development program for inflammatory
disease with Novartis. The Company's first commercialized product,
Abreva(R), is marketed in North America by GlaxoSmithKline Consumer
Healthcare and is the leading over-the-counter product for the
treatment of cold sores. Further information about AVANIR can be
found at www.avanir.com. The information contained in this press
release, including any forward-looking statements contained herein,
should be reviewed in conjunction with the company's most recent
Annual Report on Form 10-K and other publicly available information
regarding the company. Copies of such information are available
from the company upon request. Such publicly available information
sets forth many risks and uncertainties related to the company's
business and technology. Forward-looking statements often contain
such words like "estimate," "anticipate," "believe," "plan" or
"expect". Final review decisions made by the FDA and other
regulatory agencies concerning clinical trial results are
unpredictable and outside the influence and/or control of the
company. The Company disclaims any intent or obligation to update
these forward-looking statements.
Avanir (AMEX:AVN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Avanir (AMEX:AVN)
Historical Stock Chart
From Jan 2024 to Jan 2025